To hear about similar clinical trials, please enter your email below
Trial Title:
Cyclin D1 as a Prognostic Factor in Multiple Myeloma and Its Association With the Immunological Prognostic Factor PDL1 and Clinical and Biochemical Lab Tests
NCT ID:
NCT05995808
Condition:
Multiple Myeloma
Conditions: Official terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Study type:
Interventional
Study phase:
N/A
Overall status:
Not yet recruiting
Study design:
Allocation:
N/A
Intervention model:
Single Group Assignment
Primary purpose:
Diagnostic
Masking:
None (Open Label)
Intervention:
Intervention type:
Procedure
Intervention name:
Bone marow biopsy and aspiration
Description:
Bone marrow biopsy and biopsy aspiration
Arm group label:
diagnostic group
Intervention type:
Diagnostic Test
Intervention name:
biochemical and heamatological tests
Description:
complete blood count ,serum urea and creatinine
Arm group label:
diagnostic group
Other name:
complete blood count ,urea and creatinine in serum
Summary:
Multiple myeloma (MM) is the most common bone marrow malignancy of terminally
differentiated plasma cells. It accounts for about 1% of all malignant diseases and 10%
of haematological malignancies and takes the second place after non-Hodgkin lymphoma .
There are some serological and clinical criteria that help to detect the stage of MM and
predict the patients' prognosis. These criteria include the level of M protein, calcium,
haemoglobin, albumin, creatinine, β2-microglobulin and glomerular filtration rate (GFR).
Criteria for eligibility:
Criteria:
Inclusion Criteria:
1. Patients older than 18 year with newly diagnosed MM.
2. Approval to sign an informed written consent.
Exclusion Criteria:
-
1. Patient younger than 18 years. 2.Refusal to sign an informed written consent.
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Start date:
September 2023
Completion date:
August 2025
Lead sponsor:
Agency:
Sohag University
Agency class:
Other
Source:
Sohag University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05995808
